Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
Crossref DOI link: https://doi.org/10.1186/s12944-017-0493-7
Published Online: 2017-07-24
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Choi, Joshua
Khan, Amir M
Jarmin, Michael
Goldenberg, Naila
Glueck, Charles J
Wang, Ping
Funding for this research was provided by:
Lipoprotein Research Fund, Jewish Hospital of Cincinnati